Latest news

• Novartis’ Promacta receives US breakthrough therapy designation

  For rare blood disorder drug Promacta (eltrombopag), the status was awarded for its use in combination with standard immunosuppressive therapy for the treatment of patients with severe aplastic anaemia (SAA) as

• CHMP backs orphan drugs Uptravi and Coagadex

  new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP).

• Novartis bags EU approvals for three ex-GSK drugs

  year. The Swiss company announced this morning that platelet-boosting drug Revolade (eltrombopag) has become the first approved drug in the EU for adults with the rare blood disorder severe aplastic

• Novartis aims to lead immuno-oncology category

  The recent acquisition of cancer drugs from GlaxoSmithKline - which included Votrient (pazopanib), Tafinlar (dabrafenib), Mekinist (trametinib) and Promacta (eltrombopag) - added to its portfolio of targeted cancer therapies that can be combined

• Novartis gets FDA nod for rare blood disorder drug

  Promacta (eltrombopag) will be a treatment option for child patients who have had an insufficient response to corticosteroids, immunoglobins or splenectomy following its approval for adults in 2008. ... ITP who have either an insufficient response to or